Studies performed in patients with MS from Sardinia found that the presence of HERV-W products in the blood has been associated with poor prognosis (48, 51), while in the CSF it is more detected during relapses than during the remission phase (41), and its presence in CSF is associated with disability accumulation and higher relapse rate (51). Here, ERVW-1 is linked to myeloid sarcoma.